Erlonat 100mg tablet |Erlotinib | Millionpharma

                    ERLONAT 100MG

DESCRIPTION

                           Erlonat 100mg tablet has active ingredient Erlotinib, used to treat non-small cell lung cancer, pancreatic cancer and other various types of cancer. Erlonat 100mg is pharmacologically categorized as tyrosine kinase inhibitor, acts on epidermal growth factor receptor.
Erlonat 100mg tablets are prescription medicine,     Erlonat 100mg tabletused only by the patients who have valid prescription

ERLONAT 100MG

INDICATION AND USAGE

                           Erlonat 100mg is primarily indicated for; Non small cell lung cancer: Erlonat 100mg is considered as second, maintenance or greater line treatment in NSCLC. It is used after failure of some chemotherapy regimens. Erlonat 100mg is involved in     Erlonat 100mg tablet the treatment of non-small cell lung cancer patients whose cancer cells containing epidermal growth factor receptors on their surface. Erlonat 100mg tablet is not used in combination with platinum based compounds. In pancreatic carcinoma: In metastatic stage, Erlonat 100mg tablet is used in combination with gemcitabine. In this condition Erlonat 100mg is involved as first line treatment.

WARNING

                               Some of the adverse     Erlonat 100mg tablet effects occur while treating with Erlonat 100mg tablets; Interstitial lung disease Renal impairment Hepatic toxicity     Erlonat 100mg tablet with liver failure Gastrointestinal perforation Bullous &     Erlonat 100mg tablet exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia Hemorrhage Ocular disorders Embryo fetal toxicity

ERLONAT PHARMACOLOGY

                         Erlonat 100mg tablet has pharmacological effects like anti-tumor activity, which expels its action by prohibiting the intracellular phosphorylation of tyrosine kinase related with epidermal     Erlonat 100mg tablet growth factor    Erlonat 100mg tablet receptor. This EGFR is     Erlonat 100mg tablet occurs on the surface of the tumor cells. Thus results as prohibition leads to intercede with signal transduction and lead to cell lyses.

ERLONAT ADME PROPERTY

ABSORPTION

                          The peak    Erlonat 100mg tablet plasma concentration time reaches at 4 hours after drug intake After drug intake, the oral bioavailability of Erlotinib occurs as 60%, whereas a meal increases its    Erlonat 100mg tablet bioavailability to 100%. The    Erlonat 100mg tablet Erlotinib solubility is depends upon pH level. The reduction in solubility causes elevation of the pH levels. Smoking should be avoided during the treatment with Erlonat 100mg tablet , causes decreasing the exposure of Erlotinib.

DISTRIBUTION

                        Volume of distribution     Erlonat 100mg tablet of Erlotinib is 232L Human protein binding to Erlotinib 100mg tablet is occurs as 93%.

METABOLISM

                       The metabolism of Erlotinib 100mg is occurs by CYP3A4

ELIMINATION

                       The route of elimination of Erlotinib 100mgmetabolites occurs via; Feces: 83%; urine: 8% The terminal half life period of Erlotinib is 36.2 hours.

PRODUCT DETAILS

Brand : Erlonat
Ingredients : Erlotinib
Strength : 100mg
Manufactured : Natco
Package : 30 Tablets

DOSAGE ADMINISTRATION

DOSAGE MANAGEMENT

                           In NSCLC: The recommended dosage is     Erlonat 100mg tablet 150mg should be taken as a single dose by administering on an empty stomach. In pancreatic cancer: The usual dosage of Erlonat 100mg is 100mg should be taken    Erlonat 100mg tablet as a single dose by administering on an empty stomach by combining with gemcitabine. Dose alteration: In pulmonary toxicity: Erlonat 100mg Interstitial lung disease, pulmonary failure: Discontinue the Erlonat 100mg therapy In severe hepatic failure: Stop the therapy permanently
In renal impairment: Discontinue the Erlonat 100mg therapy permanently In gastrointestinal perforation and severe diarrhea:     Erlonat 100mg tablet Stop the therapy In severe Bullous and exfoliative skin disorders: Discontinue the therapy and provide supportive     Erlonat 100mg tablet measures In corneal perforation, therapy should be     Erlonat 100mg tablet discontinuing permanently. Avoid concomitant use of Erlonat 100mg tablet with CYP3A4 strong inhibitors, CYP3A4 strong inducers, cigarette smoking, gastric regulators etc.

SIDE EFFECT

SOME SERIOUS ADVERSE EFFECT

                          Renal failure Erlonat 100mg Liver toxicity Erlonat 100mg with failure Gastrointestinal perforations Ocular disorders Hemorrhage Bullous & exfoliative skin disorders Cerebrovascular disorders Hemolytic anemia & thrombocytopenia

SOME COMMON SIDE EFFECTS

                         Rash Erlonat 100mg Diarrhea Cough Dyspnea Dry skin Back pain Conjunctivitis Mucosal inflammation Pruritus Paronychia Erlonat 100mg Chest pain,    Erlonat 100mg tablet  arthralgia Musculoskeletal pain Myopathy like rhabdomyolysis while combining with lipid lowering drugs

DRUG INTERACTION

CYP3A4 INHIBITORS:

                         Concomitant use of Erlonat 100mg with CYP3A4 inhibitors like (boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketaconazole, lopinavir/ritonavir, nefazodone, nelfinavir,    Erlonat 100mg tablet posaconazole, ritonavir, saquinavir, telithromycin,     Erlonat 100mg tablet voriconazole, grapefruit or grapefruit juice) causes increasing the exposure of Erlotinib. This result as increase in risk of adverse effects related to Erlonat 100mg tablet .

IN CYP3A4 INDUCERS:

                     In combination of Erlonat Erlonat 100mg100mg with CYP3A4 inducers like anti-convulsants, rifampin, rifampicin, st Johns wort etc causes decreasing the exposure of Erlotinib. Thus results as decrease in therapeutic effect of Erlonat 100mg tablet .

CYP1A2 INDUCERS & CIGARETTE SMOKING:

                    Both are decreasing Erlonat 100mg the exposure of Erlotinib, while concomitant with Erlonat 100mg .

GASTRIC REGULATORS:

                  While    Erlonat 100mg tablet concomitant with gastricErlonat 100mg regulators like proton Erlonat 100mgpump inhibitors, H2 receptors    Erlonat 100mg tablet antagonist or antacids, Erlonat 100mgcauses depletion of Erlotinib exposure leads to loss of therapeutic effect of Erlotinib.

ANTICOAGULANTS:

                  In combination of Erlonat 100mgErlonat 100mg with warfarin, causes increasing international normalized ratio & bleeding adverse reactions. To avoid this problem, monitor the prothrombin time frequently.

PHONE NO     : +91-9940472902

EMAIL ID       : millionhealthpharmaceuticals@gmail.com

WEBSITE        : https://millionpharma.com/erlonat-100mg.php